HC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00

Key Points

• HC Wainwright has lowered the price target for Day One Biopharmaceuticals from $36.00 to $25.00, maintaining a "buy" rating for the stock.
• The company's stock is currently trading at around $6.88, significantly below the new target price, indicating a potential upside of 263.37%.
• In the latest earnings report, Day One Biopharmaceuticals posted an EPS of ($0.29), outperforming analysts' expectations of ($0.35).

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) had its price target reduced by equities research analysts at HC Wainwright from $36.00 to $25.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 309.84% from the stock's previous close. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q3 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $0.51 EPS and FY2029 earnings at $1.01 EPS.

Other analysts have also issued research reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. Needham & Company LLC decreased their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $25.33.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN traded up $0.07 during mid-day trading on Wednesday, reaching $6.10. 2,121,852 shares of the company's stock were exchanged, compared to its average volume of 2,009,409. The firm has a 50-day moving average price of $6.70 and a two-hundred day moving average price of $8.02. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $16.76. The firm has a market capitalization of $624.82 million, a price-to-earnings ratio of -6.42 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. The firm had revenue of $33.91 million for the quarter, compared to analysts' expectations of $35.55 million. Day One Biopharmaceuticals had a negative return on equity of 19.01% and a negative net margin of 50.63%. As a group, sell-side analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 4,282 shares of the firm's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the sale, the chief financial officer owned 265,231 shares of the company's stock, valued at $1,660,346.06. This trade represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Adam Dubow sold 4,552 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $28,495.52. Following the completion of the sale, the general counsel owned 47,136 shares in the company, valued at $295,071.36. This represents a 8.81% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,725 shares of company stock worth $167,299. Insiders own 6.20% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently modified their holdings of the company. Creative Planning bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $120,000. Police & Firemen s Retirement System of New Jersey raised its holdings in Day One Biopharmaceuticals by 41.1% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 17,701 shares of the company's stock worth $115,000 after purchasing an additional 5,152 shares during the period. Geode Capital Management LLC grew its stake in shares of Day One Biopharmaceuticals by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company's stock valued at $11,132,000 after acquiring an additional 171,964 shares during the period. ProShare Advisors LLC increased its stake in shares of Day One Biopharmaceuticals by 12.9% in the second quarter. ProShare Advisors LLC now owns 18,545 shares of the company's stock worth $121,000 after purchasing an additional 2,121 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in shares of Day One Biopharmaceuticals by 49.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 82,257 shares of the company's stock valued at $535,000 after purchasing an additional 27,335 shares during the period. Institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.